These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1344453)

  • 1. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
    Durdević S; Segedi D; Vejnović T; Radeka G
    Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA 125 levels in preoperative evaluation of pelvic masses.
    Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
    Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
    Roman LD; Muderspach LI; Burnett AF; Morrow CP
    J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX; Schwartz PE; Li FQ
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
    Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
    Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
    Carter PG; Iles RK; Neven P; Davies AP; Shepherd JH; Chard T
    Gynecol Oncol; 1993 Dec; 51(3):368-71. PubMed ID: 8112647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
    Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
    Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of referral guidelines for women with pelvic masses.
    Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
    Obstet Gynecol; 2005 Jan; 105(1):35-41. PubMed ID: 15625139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
    Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
    Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 125 in the diagnosis of pelvic masses.
    Mogensen O; Mogensen B; Jakobsen A
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1187-90. PubMed ID: 2767108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
    O'Connell GJ; Ryan E; Murphy KJ; Prefontaine M
    Obstet Gynecol; 1987 Dec; 70(6):930-2. PubMed ID: 3479735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
    Enakpene CA; Omigbodun AO; Goecke TW; Odukogbe AT; Beckmann MW
    J Obstet Gynaecol Res; 2009 Feb; 35(1):131-8. PubMed ID: 19215560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.